A Phase I clinical trial of UCART-22 for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) in adult patients
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2018
At a glance
- Drugs UCART-22 (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 04 Jun 2018 According to a Cellectis media release, the US FDA has approved the Companys Investigational New Drug (IND) application to initiate a Phase 1 clinical trial. The company intends to initiate the study in H2 2018.
- 09 May 2018 New trial record
- 02 May 2018 According to a Cellectis media release,The clinical research will be led by Dr. Nitin Jain, Assistant Professor, and Prof. Hagop Kantarjian, Chairman in the Department of Leukemia and University Chair in Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.